EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial

Rella Zoleko-Manego iD, Ruth Kreuzmair, Luzia Veletzky, Wilfrid Ndzebe-Ndoumba, Dorothea Ekoka Mbassi, Dearie G Okwu, Lia B Dimessa-Mbadinga-Weyat, Roselyne D Houtsa-Temgoua, Johannes Mischlinger, Matthew B B McCall, Peter G Kresmner, Selidji T Agnandji und 4 weitere

PLOS Neglected Tropical Diseases · 2023

DOI: 10.1371/journal.pntd.0011584 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS Neglected Tropical Diseases, 2023. Verfasst von Rella Zoleko-Manego und 15 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon. Hauptthemen laut MEDLINE: Albendazole, Loiasis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Österreichisches Ministerium für Bildung und Forschung, Centre de Recherches Medicales de Lambaréné, Bernhard Nocht Institute for Tropical Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is a lack of systematic evidence for strategies to control loiasis transmission in highly endemic regions. Here we assessed albendazole and ivermectin based treatment regimens to reduce Loa loa microfilaraemia in Gabon.

Methods

Eligible adult patients with L . loa microfilaraemia between 5,000 and 50,000 microfilariae/ml were randomized to either a control or one of three intervention groups (1:2:2:2 allocation ratio) consisting of three-week twice daily 400mg oral albendazole followed by 1) no treatment, 2) two further weeks of twice daily 400mg albendazole, or 3) a single dose of ivermectin in this open label randomized assessor blinded controlled clinical trial. The primary outcome was the proportion of participants with L . loa microfilaraemia ≤ 100 mf/ml at Day 168.

Results

In the efficacy-population of 42 patients 0 (0%; control group), 1 (9%; 3-week albendazole), 5 (39%; 5-weeks albendazole) and 2 (22%; 3-week albendazole plus single dose ivermectin) participants met the primary outcome of microfilaraemia below 100/ml at day 168. A 80–90% reduction of microfilaraemia was observed in the active treatment groups.

Conclusion

The 5-week regimen of albendazole or a 3-week regimen of albendazole followed by ivermectin were most efficacious to reduce microfilaraemia. All therapeutic regimens were well tolerated and safe.

Trial registration

Trial registered at the Pan-African Clinical Trials Registry: PACTR201807197019027 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlbendazoleLoiasisHumansAdultAnimalsIvermectinGabonClinical ProtocolsFishes

Substanzen

AlbendazoleIvermectin

Autor:innen und Institutionen

  • Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
  • Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • German Center for Infection Research-Partner Sites Hamburg-Lübeck-Borstel-Riems, Germany.
  • Radboud University Medical Center, Nijmegen, Netherlands.
  • Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany.
  • German Center for Infection Research-Partner Site Tübingen, Germany.

ORCID-Profile: Rella Zoleko-Manego, Michael Ramharter

Förderung

  • Österreichisches Ministerium für Bildung und Forschung
  • Centre de Recherches Medicales de Lambaréné
  • Bernhard Nocht Institute for Tropical Medicine

Zitieren

APA

Zoleko-Manego, R., Kreuzmair, R., Veletzky, L., Ndzebe-Ndoumba, W., Ekoka Mbassi, D., Okwu, D. G., Dimessa-Mbadinga-Weyat, L. B., Houtsa-Temgoua, R. D., Mischlinger, J., McCall, M. B. B., Kresmner, P. G., Agnandji, S. T., Lell, B., Adegnika, A. A., Mombo-Ngoma, G., & Ramharter, M. (2023). Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0011584

Vancouver

Zoleko-Manego R, Kreuzmair R, Veletzky L, Ndzebe-Ndoumba W, Ekoka Mbassi D, Okwu DG, et al. Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial. PLOS Neglected Tropical Diseases. 2023. doi:10.1371/journal.pntd.0011584

BibTeX
@article{ZolekoManego2023,
  author = {Zoleko-Manego, Rella and Kreuzmair, Ruth and Veletzky, Luzia and Ndzebe-Ndoumba, Wilfrid and Ekoka Mbassi, Dorothea and Okwu, Dearie G and Dimessa-Mbadinga-Weyat, Lia B and Houtsa-Temgoua, Roselyne D and Mischlinger, Johannes and McCall, Matthew B B and Kresmner, Peter G and Agnandji, Selidji T and Lell, Betrand and Adegnika, Ayôla A and Mombo-Ngoma, Ghyslain and Ramharter, Michael},
  title = {Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2023},
  doi = {10.1371/journal.pntd.0011584}
}
Kostenlos starten →